• PDF / 169,653 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 47 Downloads / 149 Views

DOWNLOAD

REPORT

---

1 S

Colonic perforation: case report In a retrospective, single-center study involving 41 patients with cancer, who received anti-angiogenesis therapy (AAT) and underwent endoscopy for antiangiogenesis-associated colitis or diarrhoea (ACD) symptoms between 1 January 2000 and 31 September 2018 at a cancer center in the USA, one man [age not stated] was described, who developed colonic perforation following treatment with bevacizumab and pazopanib for the cancer. The man, who had a history of unspecified cancer received bevacizumab and pazopanib [routes and dosages not stated]. Following the treatment, he underwent an abdomen/pelvis contrast-enhanced CT, which revealed diffusely enhancing bowel wall thickening involving distal ileum and ascending colon, suggestive of enteritis. Therefore, he was admitted and underwent colonoscopy and routine colon biopsy from a site of transmural cancer infiltration. One week after colonoscopy, colonic perforation was noted without any evidence of colitis. He received the last dose of bevacizumab 4 months before the colon perforation and pazopanib within 30 days prior to the event. It was considered that his underlying cancer, and the bevacizumab and pazopanib therapies contributed in the development of colonic perforation. He was referred for surgical treatment [outcome not stated]. Tang T, et al. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clinical Colorectal Cancer 19: e117-e123, No. 3, Sep 2020. Available from: URL: http:// 803506495 doi.org/10.1016/j.clcc.2020.03.002

0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 10 Oct 2020 No. 1825